PURPOSE: For primary melanomas, tumor thickness, mitotic rate, and ulceration are well-laid cornerstones of prognostication. However, a molecular exposition of melanoma aggressiveness is critically missing. We recently uncovered a four-class structure in metastatic melanoma, which predicts outcome and informs biology. This raises the possibility that a molecular structure exists even in the early stages of melanoma and that molecular determinants could underlie histophenotype and eventual patient outcome. EXPERIMENTAL DESIGN: We subjected 223 archival primary melanomas to a horizontally integrated analysis of RNA expression, oncogenic mutations at 238 lesions, histomorphometry, and survival data. RESULTS: Our previously described four-class structure that was elucidated in metastatic lesions was evident within the expression space of primary melanomas. Because these subclasses converged into two larger prognostic and phenotypic groups, we used the metastatic lesions to develop a binary subtype-based signature capable of distinguishing between "high" and "low" grade forms of the disease. The two-grade signature was subsequently applied to the primary melanomas. Compared with low-grade tumors, high-grade primary melanomas were significantly associated with increased tumor thickness, mitotic rate, ulceration (all P < 0.01), and poorer relapse-free (HR = 4.94; 95% CI, 2.84-8.59), and overall (HR = 3.66; 95% CI, 2.40-5.58) survival. High-grade melanomas exhibited elevated levels of proliferation and BRCA1/DNA damage signaling genes, whereas low-grade lesions harbored higher expression of immune genes. Importantly, the molecular-grade signature was validated in two external gene expression data sets. CONCLUSIONS: We provide evidence for a molecular organization within melanomas, which is preserved across all stages of disease.
PURPOSE: For primary melanomas, tumor thickness, mitotic rate, and ulceration are well-laid cornerstones of prognostication. However, a molecular exposition of melanoma aggressiveness is critically missing. We recently uncovered a four-class structure in metastatic melanoma, which predicts outcome and informs biology. This raises the possibility that a molecular structure exists even in the early stages of melanoma and that molecular determinants could underlie histophenotype and eventual patient outcome. EXPERIMENTAL DESIGN: We subjected 223 archival primary melanomas to a horizontally integrated analysis of RNA expression, oncogenic mutations at 238 lesions, histomorphometry, and survival data. RESULTS: Our previously described four-class structure that was elucidated in metastatic lesions was evident within the expression space of primary melanomas. Because these subclasses converged into two larger prognostic and phenotypic groups, we used the metastatic lesions to develop a binary subtype-based signature capable of distinguishing between "high" and "low" grade forms of the disease. The two-grade signature was subsequently applied to the primary melanomas. Compared with low-grade tumors, high-grade primary melanomas were significantly associated with increased tumor thickness, mitotic rate, ulceration (all P < 0.01), and poorer relapse-free (HR = 4.94; 95% CI, 2.84-8.59), and overall (HR = 3.66; 95% CI, 2.40-5.58) survival. High-grade melanomas exhibited elevated levels of proliferation and BRCA1/DNA damage signaling genes, whereas low-grade lesions harbored higher expression of immune genes. Importantly, the molecular-grade signature was validated in two external gene expression data sets. CONCLUSIONS: We provide evidence for a molecular organization within melanomas, which is preserved across all stages of disease.
Authors: John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Levi A Garraway; Hans R Widlund; Mark A Rubin; Gad Getz; Aaron J Berger; Sridhar Ramaswamy; Rameen Beroukhim; Danny A Milner; Scott R Granter; Jinyan Du; Charles Lee; Stephan N Wagner; Cheng Li; Todd R Golub; David L Rimm; Matthew L Meyerson; David E Fisher; William R Sellers Journal: Nature Date: 2005-07-07 Impact factor: 49.962
Authors: Véronique Winnepenninckx; Vladimir Lazar; Stefan Michiels; Philippe Dessen; Marguerite Stas; Soledad R Alonso; Marie-Françoise Avril; Pablo L Ortiz Romero; Thomas Robert; Ovidiu Balacescu; Alexander M M Eggermont; Gilbert Lenoir; Alain Sarasin; Thomas Tursz; Joost J van den Oord; Alain Spatz Journal: J Natl Cancer Inst Date: 2006-04-05 Impact factor: 13.506
Authors: W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern Journal: J Natl Cancer Inst Date: 1989-12-20 Impact factor: 13.506
Authors: A Kauffmann; F Rosselli; V Lazar; V Winnepenninckx; A Mansuet-Lupo; P Dessen; J J van den Oord; A Spatz; A Sarasin Journal: Oncogene Date: 2007-09-24 Impact factor: 9.867
Authors: Jill M Stahl; Arati Sharma; Mitchell Cheung; Melissa Zimmerman; Jin Q Cheng; Marcus W Bosenberg; Mark Kester; Lakshman Sandirasegarane; Gavin P Robertson Journal: Cancer Res Date: 2004-10-01 Impact factor: 12.701
Authors: Philip Eliades; Brian J Abraham; Zhenyu Ji; David M Miller; Camilla L Christensen; Nicholas Kwiatkowski; Raj Kumar; Ching Ni Njauw; Michael Taylor; Benchun Miao; Tinghu Zhang; Kwok-Kin Wong; Nathanael S Gray; Richard A Young; Hensin Tsao Journal: J Invest Dermatol Date: 2018-02-08 Impact factor: 8.551
Authors: Martin Lauss; Rizwan Haq; Helena Cirenajwis; Bengt Phung; Katja Harbst; Johan Staaf; Frida Rosengren; Karolina Holm; Mattias Aine; Karin Jirström; Åke Borg; Christian Busch; Jürgen Geisler; Per E Lønning; Markus Ringnér; Jillian Howlin; David E Fisher; Göran Jönsson Journal: J Invest Dermatol Date: 2015-02-23 Impact factor: 8.551
Authors: Lawrence N Kwong; Mariana Petaccia De Macedo; Lauren Haydu; Aron Y Joon; Michael T Tetzlaff; Tiffany L Calderone; Chiang-Jun Wu; Man Kam Kwong; Jason Roszik; Kenneth R Hess; Michael A Davies; Alexander J Lazar; Jeffrey E Gershenwald Journal: JCO Precis Oncol Date: 2018-06-14